title: Functional changes after treatment of optic pathway paediatric low-grade gliomas.
abstract: OBJECTIVE
  To evaluate the functional changes after treatment of paediatric optic pathway gliomas (OPGs).
  
  
  METHODS
  All patients with monofocal OPG seen from January 2004 to January 2011 were included. Best corrected visual acuity (BCVA, LogMAR), contrast sensitivity (Hiding-Heidi low-contrast 'face' test (HH) and Pelli-Robson (PR) contrast sensitivity test), and the Color Test (Ishihara plate) were obtained.
  
  
  RESULTS
  Twenty-one patients (10 boys and 11 girls with a mean age of 5.5 ± 4.4 years at diagnosis) were included in the study. Neurofibromatosis was present in four cases. Eighteen patients (85.7%) were treated with initial surgery and three patients (14.3%) with initial chemotherapy. BCVA was 0.67 ± 0.8 LogMAR at baseline and 0.62 ± 0.9 LogMAR at last visit (P=0.41). The Color test was not significantly changed at last visit (P=0.62). Contrast sensitivity with the HH test was 9.1 ± 11.1% at baseline and 3.8 ± 6.4% at last visit (P=0.03). Contrast sensitivity with PR chart was 1.33 ± 0.9 log at baseline and 1.05 ± 0.7 log at last visit (P=0.005). A reduction in contrast sensitivity at both tests was significantly greater in patients who relapsed than in patients who did not relapse (P=0.001).
  
  
  CONCLUSIONS
  After the treatment of paediatric optic pathway low-grade gliomas, a reduction in contrast sensitivity during follow-up was observed and may be correlated with tumour relapses.
authors: Pediatric Eye Department, University of Salerno, Salerno, Italy.
authors: A
authors: A
authors: Magli
authors: R
authors: R
authors: Forte
authors: G
authors: G
authors: Cinalli
authors: F
authors: F
authors: Esposito
authors: S
authors: S
authors: Parisi
authors: M
authors: M
authors: Capasso
authors: A
authors: A
authors: Papparella
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003118:Color Perception / Q000502:physiology; D015350:Contrast Sensitivity / Q000502:physiology*; D005145:Face; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D015999:Multivariate Analysis; D020339:Optic Nerve Glioma / Q000503:physiopathology* / Q000628:therapy; D014787:Vision Tests / Q000379:methods; D014792:Visual Acuity / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents
references: Neuro Oncol. 2010 Dec;12(12):1257-68
references: 20861086
references: J Child Neurol. 1999 Jun;14(6):352-6
references: 10385841
references: J Neuroophthalmol. 2011 Sep;31(3):269-78
references: 21857190
references: Childs Nerv Syst. 2006 Oct;22(10):1332-7
references: 16639629
references: Acta Neuropathol. 2007 Aug;114(2):97-109
references: 17618441
references: Eur J Pediatr. 2000 Sep;159(9):692-6
references: 11014471
references: Ophthalmology. 2012 Jun;119(6):1231-7
references: 22364864
references: Ophthalmology. 2004 Mar;111(3):568-77
references: 15019338
references: Ophthalmology. 1982 Jan;89(1):68-72
references: 7070777
references: J Child Neurol. 2003 Jul;18(7):471-8
references: 12940652
references: J Neurosurg. 1988 Jan;68(1):85-98
references: 3275755
references: Pediatr Neurosurg. 2000 Mar;32(3):132-6
references: 10867559
references: Am J Ophthalmol. 2011 Mar;151(3):542-9.e2
references: 21232732
references: Pediatr Blood Cancer. 2006 May 1;46(5):586-96
references: 16411210
references: Surv Ophthalmol. 1994 Mar-Apr;38(5):427-52
references: 8009427
references: Neurosurg Focus. 2007;23(5):E2
references: 18004964